NTT DATA Named a Leader in IDC MarketScape for Worldwide Cloud Professional Services
10.7.2024 15:00:00 EEST | Business Wire | Press release
NTT DATA, a global digital business and IT services leader, today announced it has been named a Leader in the IDC MarketScape: Worldwide Cloud Professional Services 2024 Vendor Assessment report (Doc #US51406224, June 2024)
The report evaluated 24 cloud professional services providers on key measures of success across two primary categories: capabilities and strategies. IDC recognized NTT DATA for the evolution of its cloud professional services over the last two years, citing its integrated capabilities to create a broader portfolio of IT and connectivity services, wider industry-focused consulting, and more global scale.
IDC recognized NTT DATA for its broad range of digital offerings includes business consulting, data & intelligence, customer experience & design, network and application services, cybersecurity, and cloud and IT infrastructure. The report noted the evolution of NTT DATA’s cloud professional services as a particular strength, as it expanded not only the breadth of its offering, but also its tooling and methods. The company's other strengths include sales and distribution, as well as its customer retention strategies.
"A strength of NTT DATA is the evolution of its cloud professional services over the past two years, expanding not only its offering breadth but also its tooling and methods," said Gard Little, Research Vice President, IDC. "Clients noted NTT DATA's high level of technical capabilities for cloud modernization and migration, as well as for agile development. Likewise, clients have appreciated the results NTT DATA can deliver related to the automation of operational areas such as application releases."
The IDC MarketScape cited cloud clients should consider choosing NTT DATA when seeking “a service provider whose focus is on trust and long-term client relationships.” The report notes that while NTT DATA employs a strategy to deliver greater value based on regional needs, its hybrid culture, and differentiation, is based on its Japanese roots. It also highlighted that NTT DATA’s focus on sustainability and social responsibility is deeply embedded in its corporate DNA, going back to its founding in 1988.
“At NTT DATA, we believe a seamless cloud journey starts with flexibility. Our NTT DATA unified Cloud Adoption Framework (NuCAF) integrates with all major hyperscalers, ensuring a smooth migration and transformation for our clients,” said Hidehiko Tanaka, Head of Technology and Innovation General Headquarters of NTT DATA. “We're doubling down on this commitment by making strategic acquisitions and investments in cutting-edge technologies like generative AI, All-Photonics Network, and smart robotics, alongside key partnerships to propel our clients forward in a sustainable and secure digital future."
According to the report, clients noted “NTT DATA’s high level of technical capabilities for cloud modernization and migration, as well as for agile development.” Clients also appreciate the results NTT DATA can deliver with regard to the automation of operational areas such as application releases.
“We are honored to be recognized as a Leader in the IDC MarketScape for Worldwide Cloud Professional Services,” said Charlie Li, Global Head of Cloud and Security Services of NTT DATA. “This acknowledgement underscores our commitment to delivering business value through a cohesive, full-stack modern portfolio. Over the past two years, we’ve enhanced our AI powered offerings and methodologies tailored to industry needs. IDC’s recognition highlights our strengths in client trust, expertise, and comprehensive cloud capabilities. We remain focused on leveraging our global scale and platform delivered services to drive innovation and exceptional customer experiences.”
About NTT DATA
NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. We invest over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future. As a Global Top Employer, we have diverse experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, industry solutions, as well as the development, implementation and management of applications, infrastructure, and connectivity. We are also one of the leading providers of digital and AI infrastructure in the world. NTT DATA is part of NTT Group and headquartered in Tokyo. Visit us at nttdata.com.
About IDC MarketScape
IDC MarketScape vendor analysis model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research methodology utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier's position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709459471/en/
Contacts
Global Marketing & Communications Headquarters
NTT DATA Group Corporation
global-marketing@kits.nttdata.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom